News · 26 weeks66+11%
2026-03-012026-08-23
Mix3990d
- Insider22(56%)
- SEC Filings11(28%)
- Other6(15%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERChief Technical Ops Officer Dhaliwal Harpreet S. exercised 17,000 shares at a strike of $24.79 and sold $935,068 worth of shares (17,000 units at $55.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Wassil Jim exercised 2,250 shares at a strike of $5.35 and sold $121,195 worth of shares (2,250 units at $53.86) as part of a pre-agreed trading plan (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERPRESIDENT AND CFO Guggenhime Andrew exercised 10,000 shares at a strike of $5.35 and sold $538,879 worth of shares (10,000 units at $53.89) as part of a pre-agreed trading plan (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form 10-Q filed by Vaxcyte Inc.10-Q - Vaxcyte, Inc. (0001649094) (Filer)
- SECVaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte Reports Second Quarter 2026 Financial Results and Provides Business UpdateTopline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027 Approximately $2.5 Billion in Cash, Cash Equivalents and Investments as of June 30, 2026 SAN CARLOS, Calif.,
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant sold $1,012,375 worth of shares (18,198 units at $55.63) as part of a pre-agreed trading plan and exercised 16,198 shares at a strike of $2.03 (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERSEC Form 4 filed by Director Markels John4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERNew insider Markels John claimed no ownership of stock in the company (SEC Form 3)3 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECVaxcyte Inc. filed SEC Form 8-K: Leadership Update8-K - Vaxcyte, Inc. (0001649094) (Filer)
- PRVaxcyte to Participate in Upcoming Investor ConferencesSAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: Leerink Partners Therapeutics Forum, July 14-15, 2026: Meetings will take place on Wednesday, July 15.BTIG Virtual Biotechnology Conference, July 28-29, 2026: Meetings will take place on Tuesday, July 28. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluat
- INSIDERPRESIDENT AND CFO Guggenhime Andrew exercised 10,000 shares at a strike of $5.35 and sold $572,837 worth of shares (10,000 units at $57.28) as part of a pre-agreed trading plan (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Wassil Jim exercised 516 shares at a strike of $5.35 and sold $126,736 worth of shares (2,250 units at $56.33) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 156,760 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant sold $1,338,270 worth of shares (24,237 units at $55.22) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 452,466 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECSEC Form 144 filed by Vaxcyte Inc.144 - Vaxcyte, Inc. (0001649094) (Subject)
- INSIDERSEC Form 4 filed by Director Slaoui Moncef4 - Vaxcyte, Inc. (0001649094) (Issuer)
- INSIDERNew insider Slaoui Moncef claimed no ownership of stock in the company (SEC Form 3)3 - Vaxcyte, Inc. (0001649094) (Issuer)
- SECVaxcyte Inc. filed SEC Form 8-K: Leadership Update8-K - Vaxcyte, Inc. (0001649094) (Filer)
- INSIDERCHIEF EXECUTIVE OFFICER Pickering Grant exercised 225 shares at a strike of $1.79 and sold $1,284,205 worth of shares (24,461 units at $52.50) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 474,703 units (SEC Form 4)4 - Vaxcyte, Inc. (0001649094) (Issuer)
PCVX FAQ
7 questionsWhat does Vaxcyte Inc. do?
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020...Where does PCVX stock trade?
Vaxcyte Inc. (PCVX) is listed on NASDAQ.What sector and industry is PCVX in?
Vaxcyte Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vaxcyte Inc. go public?
Vaxcyte Inc. (PCVX) completed its IPO in 2020.What are analysts saying about PCVX?
Vaxcyte Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-01-07. Recent price targets cluster around $3800.00.What companies are similar to PCVX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PCVX side-by-side with any of them on Quantisnow.How can I track PCVX on Quantisnow?
Quantisnow aggregates Vaxcyte Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCVX to receive live email and push alerts on every new disclosure.